Identification of established and novel extracellular matrix components in glioblastoma as targets for angiogenesis and prognosis

Lucas Cunha Barbosa[1,3], Gabriel Cardoso Machado[1,3], Manoela Heringer[2], Valéria Pereira Ferrer[1,3]

1. *Graduation Program of Pathological Anatomy, Faculty of Medicine, Federal University of Rio de Janeiro*
2. *Brain's Biomedicine Lab, Paulo Niemeyer State Brain Institute, Rio de Janeiro, Brazil*
3. *Laboratory of Cellular and Molecular Biology of Tumors, Department of Cellular and Molecular Biology, Institute of Biology, Fluminense Federal University, Niteroi, Brazil*

Abstract

Glioblastomas (GBM) are aggressive tumors, characterized by heterogeneity, high proliferation and infiltration, resistance to treatments, and abundant vasculature. Angiogenesis, the formation of new vessels from pre-existing ones, involves endothelial cells (EC) migrating and proliferating to form new tubes. Various extracellular matrix (ECM) molecules can modulate EC survival, migration, and proliferation. In this study, we cultured human brain EC (HBMEC) on GBM-derived ECM and found that GBM ECM inhibited EC proliferation and modulated the branching process (average vessel length, number of junctions, and vessel endpoints) compared to the HBMEC ECM control. Through *in silico* analysis, we investigated whether GBM influences the expression of ECM molecules in EC and which of these molecules directly impact the overall survival (OS) of GBM patients. We observed increased expression of collagen alpha chains (COL5A3, 6A1, 22A1, and 27A1), laminin alpha and beta chains (LAMA1 and B1), fibulins (FBLN1 and 2), metalloproteinase (MMP)-9, hyaluronan synthase (HAS)1, integrin alpha chain (ITGA)3, transforming growth factor beta-1 (TGFB1), and wingless-related integration site (Wnt)-9B in EC influenced by GBM compared to normal brain EC. Furthermore, our study demonstrated that the expression of these ECM molecules, along with neurocan (NCAN), directly influenced the OS of GBM patients. In conclusion, this study identifies both established and novel ECM molecules that can regulate GBM angiogenesis and highlights NCAN, COL22A1, and COL27A1 as potential new biomarkers for GBM prognosis.

keywords: extracellular matrix, glioblastoma, endothelial cells, biomarkers, prognosis

Highlights

- The GBM-derived ECM inhibited the proliferation of HBMEC *in vitro*
- EC from GBM exhibited heightened expression of multiple ECM and ECM-related molecules
- The increased expression of ECM molecules linked to worse prognosis in GBM patients

- We identified COL5A3, LAMA1, WNT9B and HAS1 transcripts as possible modulators of GBM angiogenesis
- COL27A1 and NCAN genes may be new biomarkers to assist GBM prognosis

Introduction

Adult diffuse gliomas are brain tumors that originate from glial cells. These tumors are currently categorized into three subtypes: (1) astrocytoma with mutations in the isocitrate dehydrogenase (IDH) gene; (2) oligodendroglioma with IDH mutations and chromosome 1p/19q-codeletion; (3) GBM, which is the most aggressive type of glioma, IDH wild-type followed by at least one of these characteristics: amplification of the EGFR gene, mutation in the TERT promoter, and/or the concurrent gain of chromosome 7 and loss of chromosome 10 (+7/−10), necrosis and microvascular proliferation (Brat et al., 2018; Louis et al., 2021). The median survival time after GBM diagnosis is still around 15 months, and the 5-year overall survival rate is only 6.8% (Wen et al., 2020).

GBM growth depends on the formation of new blood vessels, and it is one of the most vascularized tumors (Takano et al., 2010). Blood vessels developed in the primary tumor are larger than normal counterparts and follow a crisscross path, with bigger and irregular lumen diameters, highly permeable, and irregularly branched (De Bock et al., 2011). The tumor vasculature is hyperpermeable to plasma leading to local edema and extravascular clotting of plasma (Mazzone et al., 2009; Nagy et al., 2010), altered blood flow and flux of leukocytes in the tumor site (Folkins et al., 2009), and spread of tumor cells (Papetti and Herman, 2002; Pen et al., 2007). The leakiness of vessels leads to large volumes of tumor tissue without blood flow and obstructs the delivery of drugs, oxygen, and nutrients resulting in ischemia and necrotic regions within the tumor (Baish et al., 2011; Stylianopoulos and Jain, 2013).

Angiogenesis is a complex process involving proliferation, migration, and differentiation of vascular EC under stimulation of specific signals (Onishi et al., 2013). In brief, the lack of oxygen in the EC stimulates the increase and release of pro-angiogenic growth factors such as vascular endothelial growth factor (VEGF) (Stacker et al., 2001; Weathers and de Groot, 2015), TGFB1 (Pepper et al., 1993; Burghardt et al., 2021), Stromal-derived Factor 1 (SDF-1) (Rempel et al., 2000; Gonçalves et al., 2023), angiopoetins (Stratmann et al., 1998; Labussière et al., 2016), among others (Ahir et al., 2020). These angiogenic factors bind to their receptors on the EC membrane leading to the stimulation for dissolution of the vessel wall and degradation of the EC basement membrane (BM) and the surrounding ECM (Senger and Davis, 2011). Following the degradation of the BM, specific proteases such as MMP remodel the ECM components (De Oliveira Rosario et al., 2020) and a new matrix is synthesized by stromal cells which in turn promote the migration and proliferation of EC resulting in the formation of an endothelial tube-like structure (Lakka and Rao, 2008). Then, a mature vascular basement membrane is formed around the newly formed endothelial tube and the pericytes and smooth muscle cells surrounding it resulting in a stable new vessel (Onishi et al., 2013).

The brain and GBM ECM are enriched in hyaluronic acid; proteoglycans such as NCAN and versican; and glycoproteins such as tenascin and fibronectin (Alves et al., 2011a; Yang and Yee, 2013; Ferrer, 2018). The ECM molecules by themselves trigger EC signaling through activation of specific membrane receptors and modulate access to stored growth factors assisting several processes in angiogenesis such as EC attachment and detachment, EC survival, proliferation and migration (Senger and Davis, 2011; Onishi et al., 2013). The mechanical properties of the ECM also contribute to modulating these angiogenic processes (Kretschmer et al., 2021). Therefore, ECM molecules can have both pro- and antiangiogenic effects (Petrik et al., 2010; Rupp et al., 2016).

Certain ECM components are already well known to modulate GBM angiogenesis, such as tenascin C (Zagzag et al., 1995; Behrem et al., 2005; Rupp et al., 2016), collagens I, IV and VI (Yunker et al., 2008; Mammoto et al., 2013), hyaluronan (HA) (Liu et al., 1996), laminin (Ljubimova et al., 2006), versican and fibronectin (Yang and Yee, 2013). Due to the importance of ECM and vascularity to the GBM aggressiveness and the dual angiogenic effects of ECM components, we proposed to study the influence of GBM ECM in EC proliferation, branching and ECM expression with or without GBM influence. We also evaluated the direct contribution of some ECM molecules in the OS of GBM patients *in silico*.

Experimental procedures

Cell Culture

The GBM cells (GBM02) was established by Professor Vivaldo Moura-Neto's group (Paulo Niemeyer State Brain Institute) from surgical resection of a human tumor in the year of 2002 (Faria et al., 2006), and cordially provided for this study. The HBMEC lineage originated from Prof. Dennis Grab Lab (Department of Pathology, Johns Hopkins School of Medicine) (Stins et al., 2001) was generously provided by Professor Catarina Freitas' research group. The cells were thawed from liquid nitrogen and plated in 75 cm2 cell culture flasks containing Dulbecco's Modified Eagle Medium/Ham's F12 media (DMEM/F-12) supplemented with 10% fetal bovine serum (FBS). The cells were maintained in a humidified incubator with 5% CO_2 at 37°C.

Formation of ECM-free of cells

$5x10^4$ HBMECs (control) or GBM02 were cultured on glass coverslips coated with 0.1% bovine gelatin in 24-well plates (Bhattacharyya et al., 2010). Cells were maintained in a humidified incubator with 5% CO_2 at 37°C in DMEM-F12 supplemented with 10% FBS. After 72 h of cultivation, cells were lysed using a buffer containing 0.1% Triton X-100 and 0.1 M NH_4OH in PBS at 4°C. Gentle washes with PBS were performed to eliminate cellular debris (Alves et al., 2011a). The remaining protein network, invisible under an optical microscope, was termed the pre-formed ECM-free of cells.

HBMEC immunofluorescence and proliferation assay

$5x10^4$ HBMECs were cultivated under HBMEC ECM (control) or GBM ECM in a 24-well plate covered by 0.1% gelatin for 24 h, 48 and 72h. At the time points, the cells were

fixed with 4% paraformaldehyde (PFA)/PBS for 20 min, permeabilized with 0.1% Triton X-100/PBS, and blocked with 5% BSA/PBS for 1 h (De Oliveira Rosario et al., 2020). The coverslips were then treated with 0.165 μM of Alexa Fluor 488 phalloidin solution (A12379, Invitrogen) for 30 min and washed with PBS. Then, they were stained with DAPI (4',6-diamino-2- phenylindole) at 1 μL/mL (D9542 Sigma-Aldrich®) and mounted on glass slides using Fluoromount-G®. The cells were imaged at 20x using a DMi8 advanced fluorescence microscope (Leica Microsystems, Wetzlar, Germany) and analyzed with Leica LAS AF Lite. The images were processed, and nuclei counted using the software Fiji for ImageJ software version 1.52 (Wayne Rasband, National Institutes of Health, MD, USA). The analyses were performed using three biological replicates and statistics were performed using analysis of variance (ANOVA) in GraphPad Prism version9.

AngioTool

Angiotool software version 0.6 (National Institutes of Health®, Bethesda, Maryland, United States) was free downloaded and used. This software measured the "sprouting activity" (Zudaire et al., 2011) of the HBMEC fluorescent images from proliferation assay (Fig.2A). The software skeletonizes and analyzes the area of interest. The vessel percentage area, total vessel length, average vessel length, total number of junctions and endpoints were analyzed and extracted by the software. Motion or doubling artifacts, blurry images, quality scores lower than 40, or poor centration were exclusion criteria of the analysis (Hunt et al., 2022).

Bioinformatic analysis

Influence of GBM microenvironment in the ECM transcripts of EC

A curated database of EC transcriptomics data (EndoDB, https://endotheliomics.shinyapps.io/endodb/) was used to download transcripts data from EC (Khan et al., 2019). We selected the E-GEOD-9861, E-MTAB-5686, and E-MTAB-765 (Banerjee et al., 2011) studies to obtain data on 11 samples of EC from normal brains. Additionally, we chose the E-MEXP-2891 (Ricci-Vitiani et al., 2010) study, from which we obtained data on 6 samples of EC from GBM specimens. We compared the expression of a set of ECM molecules (among proteoglycans, glycoproteins, synthesizing- and degrading-enzymes and stored growth factors) between normal and GBM data. First, we performed the D'Agostino-Pearson normality test and then used the Mann Whitney test for statistical analysis. The statistics analysis and graphs were performed using GraphPad Prism version9.

OS curves

Survival data was utilized to ascertain the ultimate recorded day of the patient's survival. Comparative analyses of survival among the specified genes were executed employing the Kaplan-Meier methodology and the log-rank (Mantel-Cox) statistical test via GraphPad Prism version9. We selected the ECM molecules which presented interesting

results in the EC expression analysis to verify the influence of its expression directly in the OS of patients with GBM. Using the transcriptome information of The Human Protein Atlas (https://www.proteinatlas.org/) (Karlsson et al., 2021) and The Cancer Genoma Atlas (TCGA) database (https://www.cbioportal.org/) (Cerami et al., 2012; Gao et al., 2013) (N = 153), we divided the patients between high and low expression. The best expression cut-off referred to the value that yielded maximal difference with regard to survival between the two groups at the lowest log-rank P-value and was performed in The Human Protein Atlas site. The median survival was determined as the minimal survival time at which the survival function equaled or fell below 50%.

Results

The GBM-derived ECM suppressed the proliferation of HBMEC

Initially, we investigated whether GBM ECM influenced the proliferation rate of HBMEC at 24, 48 and 72 h. We observed that at 24 h GBM ECM significantly suppressed the HBMEC proliferation rate (**p <0.01) compared to gelatin coverslip control (Fig. 1A). However, at 48 h HBMEC exhibited similar proliferation rates across all tested conditions (Fig. 1B). Notably, at 72 h, GBM ECM continued to inhibit HBMEC proliferation (** p <0.01) compared to HBMEC ECM (Fig. 1C). These results collectively demonstrate that GBM ECM can reduce the proliferation rate of HBMEC.

The ECM-derived from GBM influenced the branching process of HBMEC *in silico*

The HBMEC did not form tubes under the tested conditions, we decided to assess potential alterations in sprouting activity *in silico*. To achieve this, we employed the angiotool software, which skeletonizes immunofluorescence images (obtained previously in the proliferation assay) to visualize the vascular network (Fig. 2A). Our analysis revealed no significant changes in the percentage area over the observed time (Fig. 2B). However, both GBM and HBMEC ECM decreased the average vessel length at 48 h (***p < 0.001) compared to gelatin coverslips (Fig. 2C). Furthermore, at 48 h, both ECM types reduced the number of junctions (Fig. 2D, ***p < 0.001), whereas at 72 h, they increased the number of junctions comparatively to gelatin (***p < 0.001). Additionally, at 72 h GBM ECM inhibited the number of endpoints compared to HBMEC ECM (Fig. 2E, **p < 0.01). Overall, these findings demonstrate the dynamics of HBMEC branching under both HBMEC and GBM ECM depend on time.

EC exhibited increased expression of numerous ECM-related molecules under the influence of GBM microenvironment

Once GBM ECM modulated the proliferation and branching of HBMEC, we sought to investigate whether the GBM microenvironment would alter the EC transcriptome profile of ECM-related molecules. To accomplish this, we utilized the EndoDB database. We observed that the GBM microenvironment increased the expression of several ECM components in EC (Fig. 3): COL5A3, COL22A1, COL27A1, LAMA1, LAMB1, FBLN1

(***p <0.001); COL6A1 and FBLN2 (**p <0.01). However, there were no significant differences in the expression of COL5A1 and NCAN in EC. We observed that EC from GBM specimens exhibited increased expression of the ECM-stored growth factors TGFB1 and WNT9B (**p <0.01), as well as the ECM-regulatory proteins MMP9 (***p< 0.001), HAS1 and ITGA3 (**p<0.01), Fig. 4. However, there were no significant differences in the expression of TIMP-4 between normal and GBM EC. Overall, our findings demonstrate that GBM upregulates the expression of several key ECM components in EC.

The enhanced expression of several ECM molecules was associated with a poorer prognosis in patients with GBM

This investigation aimed to assess whether elevated levels of ECM transcripts correlate with OS of patients with GBM. We analyzed the same molecules analyzed in EC transcriptome analysis, dividing the GBM cohort in high and low expression groups. Our findings revealed significant associations. Specifically, patients with high expression of COL5A1 showed a median survival of 10.41 months, whereas those with low expression had a median survival of 14.92 months (**p = 0.0021). Similarly, for COL5A3, median survival was 11.24 months in high-expression patients compared to 15.12 months in low-expression patients (*p = 0.0114). The data for COL6A1 indicated median survivals of 11.74 and 14.93 months, respectively (*p = 0.0102). For COL22A1, the median survival was 12.66 months in the high-expression group and 19.23 months in the low-expression group (***p = 0.0008). Notably, COL27A1 showed median survivals of 11.74 and 16.6 months for high and low expression, respectively (**p = 0.0014). Regarding FBLN1, patients with high expression exhibited a median survival of 11.28 months, whereas those with low expression had a survival of 16.64 months (**p = 0.0015). For the FBLN2 high-expression group, the survival was 11.84 months compared to 14.04 months in the low-expression patients (p = 0.1116). In the case of ITGA3, the observed survivals were 10.42 months versus 14.42 months, respectively (**p= 0.0038). Laminin analysis revealed that patients with high expression of LAMA1 had a median survival of 12.76 months compared to 17.49 months for the low-expression cohort (*p = 0.0122). Similarly, for LAMB1, the medians were 11.24 versus 14.93 months, respectively (**p = 0.0083). High expression of TGFB1 (8.84 versus 14.93, **p=0.047), MMP9 (10.82 versus 14.73, *p=0.0149), and HAS1 (11.01 versus 14.73, *p=0.0313) also correlated with a worse prognosis. Notably, NCAN was the sole ECM molecule analyzed that exhibited a better prognosis in the high-expression group, with median survivals of 14.73 months versus 11.84 months (*p = 0.0124). In summary, the increased expression of most analyzed ECM molecules, which were also elevated in EC, was associated with a negative impact on the OS of patients with GBM.

Discussion

GBMs are considered highly angiogenic tumors, and angiogenesis in these tumors is associated with malignancy levels and shows a negative correlation with patient survival (Zhang et al., 2008; Alves et al., 2011b). During GBM development, tumor cells play an early instructive role on the brain parenchyma. Tumor-instructed stromal cells

have differential effects on tumor cell proliferation and migration *in vitro*, indicating a reciprocal crosstalk between neoplastic and non-neoplastic cells, such as EC (Bougnaud et al., 2016; Testa et al., 2022). The composition of ECM and its stored-signaling factors also influence the behavior of GBM cells and GBM stromal cells, affecting GBM angiogenesis, infiltration and aggressiveness (Alves et al., 2011a; Dinevska et al., 2023; Marino et al., 2023). Understanding the complex interplay between the ECM, GBM cells and EC in the tumor angiogenesis and aggressiveness is crucial for finding new biomarkers to improve patient outcomes and for the development of targeted therapies.

To study the proliferation of HBMEC *in vitro*, a crucial step in the angiogenesis, we initially standardized a decellularized ECM from GBM (Ahir et al., 2020; Testa et al., 2022). We utilized gelatin coating to preserve the retention and biophysical properties of the ECM derived from GBM cells (Pedron and Harley, 2013; Harris et al., 2018). Using this model, our findings indicated that GBM ECM led to a reduction in HBMEC proliferation rates at 24 h and 72 h, but not at 48 h. Furthermore, in an *in silico* vessel network model, we observed that HBMEC cultured with GBM ECM exhibited fewer endpoints in comparison to those cultured with HBMEC ECM at 72 h. In a similar but slightly different model, Alves et al. (2011) cultured EC from human umbilical veins (HUVECs) on ECM produced by U373 MG glioma cells. Initially, HUVECs adhered to the immobilized U373 MG matrix, however, a significant proportion detached and underwent anoikis (50 to 80%) within 24 h compared to cells incubated with control matrices. They showed that the surviving EC (20 to 50%) exhibited an increase in proliferation, however, these EC formed 74-97% fewer tube-like structures *in vitro* than those grown on non-tumoral matrices (Alves et al., 2011a). It is important to note that both reduced proliferation and decreased tube formation are critical for creating a hypoxic environment in GBM and increasing angiogenesis later. The dynamics of tumor angiogenesis are very complex and dependent on time (Ahir et al., 2020; Lee et al., 2022).

We subsequently examined whether the expression of ECM molecules would be altered in EC under the influence of the GBM microenvironment, using an EC transcriptome database. We observed that the expression levels of most ECM and ECM-related molecules analyzed were increased in EC from GBM compared to those from normal brain EC. Additionally, we found a general correlation between the increased expression in GBM EC, high expression in GBM tissue, and OS in these patients.

Another analysis of the EC transcriptome also demonstrated deregulation of genes involved in cell proliferation, angiogenesis, and ECM deposition in the vasculature of GBM (Schaffenrath et al., 2021). We observed enhanced expression of specific collagen subtypes (V, VI, XXII, and XXVII) in EC from GBM. COL6A1 and the vascular endothelial molecular marker cluster of differentiation 31 (CD31) showed positive correlations in *in vivo* assays. Alterations in the expression of COL6A1 and CD31 induced glioma angiogenesis (Han et al., 2022). Additionally, physical compaction of human GBM cell lines U87MG, U251, and LN229 induced the expression of collagen VI and the collagen crosslinking enzyme lysyl oxidase, and upregulated the expression of the angiogenic factor VEGF (Mammoto et al., 2013). In another study, the authors developed a novel nomogram based on angiogenesis-related genes, such as COL22A1, which allowed survival prediction in patients with grade 4 diffuse gliomas (Liu et al., 2023). Although loss of COL22A1 copy number was linked to lower survival in a pool

of low-grade gliomas (LGG) and GBM patients, significant differences in COL22A1 expression were not observed. The correlation between COL22A1 expression and survival was not supported by their study (Spainhour and Qiu, 2016).

In turn, COL5A1 has previously been associated with survival patterns in GBM patients ($p < 0.0001$). Their results indicate that COL5A1 had the highest ranking, with significantly higher expression levels in GBM tissues compared to normal brain tissues. Moreover, COL5A1 was overexpressed in samples exhibiting aggressive characteristics, including the non-G-CIMP ($p < 0.0001$), IDH1 wild-type ($p < 0.0001$), and unmethylated O^6-methylguanine-DNA methyltransferase (MGMT) groups ($p = 0.008$). Regarding the molecular subtype classification of GBM, the expression level of COL5A1 in the mesenchymal (Mes) type was higher than that in the proneural and classical subtypes ($p < 0.001$) (Tsai et al., 2021). The expression of COL5A3 was also correlated with poor survival in GBM (Bassot et al., 2023). Additionally, immunohistochemistry assays demonstrated that COL6A1 was significantly upregulated in tumor tissues of high-risk GBM patients. Their single-cell RNA sequencing work also validated those malignant cells expressed high levels of COL6A1 (Wan et al., 2023). Altieri et al. (2019) identified a network of gene mutations associated with survival, including COL5A3 and LAMA2 ($p < 0.05$). However, none of these gene mutations was associated with survival when considered in isolation (Altieri et al., 2019). Therefore, our study is the first to directly correlate high expression of COL5A3 with a modulated profile of EC in GBM, and the first to associate COL27A1 with poor survival in the GBM cohort.

Laminins are the major components of blood vessel basement membranes (BM) (Yousif et al., 2013). The upregulation of LAMB1 expression has been strongly correlated with the downregulation of miR-124-5p. Restoring miR-124-5p expression has been shown to suppress glioma growth by inhibiting angiogenesis, a phenomenon also observed upon LAMB1 knockdown (Chen et al., 2014). Additionally, using a zebrafish model with LAMA5, it was discovered that LAMA5 doubled the formation of blood vessel-dependent GBM microtumors. Despite LAMA5 being a known attachment site for GBM, its expression had no effect on the association of tumor cells with blood vessels (Gamble et al., 2018). In turn, the LAMA1 chain is a component of various laminin isoforms (laminin-1, -2, -6, -8, -10, -12) (Patarroyo et al., 2002). These laminin chains have been previously found to be secreted by glioma cells, playing roles in peritumoral infiltration through the adhesion of cancer cells to ECM components and cellular migration (Kawataki et al., 2007). Lower expression of LAMA1 has been associated with improved survival in GBM patient datasets, whereas LAMA1 overexpression has been correlated with increased tumor growth in primary GBM (Scrideli et al., 2008; Fiscon et al., 2018). LAMB1 has been described as a promising candidate biomarker in GBM (Zolotovskaia et al., 2022). Low levels of LAMB1 have also been associated with a less invasive tumor phenotype and a better prognosis (Virga et al., 2017). To date, there have been no manuscripts indicating the relationship between LAMA1 expression and EC in GBM or GBM angiogenesis.

Fibulins are elastic fiber–associated proteins. Bioinformatics analysis has demonstrated that angiogenesis-related pathways are increased from low- to high-grade astrocytomas, with differentially expressed proteins validated, including fibulin (Ren et al., 2016). FBLN7 is markedly overexpressed in GBM tissue compared to other astrocytic

tumors, according to recent cancer microarray databases. FBLN7 was found to immunolocalize mainly to EC and pericytes of glomeruloid and hypertrophied microvessels (de Vega et al., 2019). In addition, a 39 kDa recombinant human FBLN3 has been shown to reduce blood vessel density by 70% in FBLN3-treated GBM xenografts compared with controls. Matrigel assays demonstrated the suppressive effect of this fibulin on angiogenesis. Additionally, this molecule was observed to play a role in vasculogenic mimicry in GBM (Ke et al., 2020). The overexpression of FBLN1 (also known as EFEMP1) has been shown to eliminate tumor development and suppress angiogenesis, cell proliferation, and VEGFA expression. In GBM cells treated with exogenous FBLN1 protein or overexpressed endogenous FBLN1, the level of EGFR was reduced, leading to attenuated AKT signaling activity (Hu et al., 2011).

Consistent with our findings, FBLN1 has been validated as a protein highly expressed on the surface of human gliomas, with predicted influence on glioma progression (Towner et al., 2013). Conversely, a study involving 95 GBM patients analyzed by qPCR demonstrated that FBLN1 was a favorable prognostic marker for patients with GBM according to Cox regression analysis (Hu et al., 2011). On the other hand, FBLN2 down-regulation was also associated with the advanced clinical stage of astrocytoma tissues (Ren et al., 2016). These apparently conflicting results may be explained by the size of the analyzed cohorts, our classification of patients into high and low FBLN1 expression groups, and the inclusion of only wild-type GBM patients in our cohort. However, it is important to note that further studies are necessary to elucidate the relationship between FBLN1 and -2 expression and GBM prognosis.

Our study identified TGFB1 as one of the overexpressed growth factors in GBM EC. Integrative bioinformatic analysis confirmed the key role of TGFB1 as a major interaction module shaping GBM progression (Bougnaud et al., 2016). TGFB1 was found to enhance GBM-induced angiogenesis, a process that was impaired by a c-Jun N-terminal kinase (JNK) inhibitor (SP600125) but not by extracellular signal-regulated kinase (ERK), phosphatidylinositol 3-kinase (PI3K), or mitogen-activated protein kinase (MAPK) inhibitors. These findings underscore the critical role of TGFB1 and JNK pathways in mediating GBM angiogenesis (Yang et al., 2013; Han et al., 2015). TGFB1 expression was also positively associated with aggressive prognosis, as it was higher in the Mes subtype of high-grade glioma (HGG) compared to the proneural subtype. Overall survival analysis of GBM patients revealed that those in the top 50% TGFB1 expression group survived significantly shorter time than those in the bottom. TGFB1 emerged as a potential prognostic molecule and a potential signature gene for Mes subtype HGG (Pan et al., 2018). Furthermore, insulin-like growth factor 1 (IGF-1) was found to be linked to TGF-β signaling in regulating the mesenchymal transition and cell invasion of GBM through inhibition of miR-4286 *in vitro* (Ho et al., 2022).

Furthermore, certain WNT variants have been implicated in the angiogenesis process of GBM (Riganti et al., 2014; McCord et al., 2017). The WNT signaling pathway is necessary for angiogenesis in the CNS and BBB differentiation. β-catenin, a component of the WNT signaling pathway, serves as a marker for proliferating EC in adult GBM (Manoranjan and Provias, 2022). Phosphorylation of β-catenin at Ser675 and activation of the WNT signaling pathway induced the expression of multidrug resistance-associated protein-1 (MRP-1), leading to EC stemness-like activation and chemoresistance (Huang et al., 2020). Additionally, WNT5A expression was not affected following treatment of HBMEC with GBM-conditioned media pool (De Oliveira Rosario et al., 2020). To our

knowledge, this study is the first to describe a potential role of WNT9B expression in EC in GBM angiogenesis.

Interestingly, an anti-integrin-based approach to inhibit GBM angiogenesis represents an alternative strategy to the traditional focus on anti-VEGF therapies (Seystahl and Weller, 2012; Paolillo et al., 2016). For example, ITGB8 has been identified as an essential regulator of GBM-induced angiogenesis. Tumors that are highly angiogenic and poorly invasive exhibit low levels of β8 integrin, whereas highly invasive tumors with limited neovascularization express high levels of β8 integrin (Tchaicha et al., 2011). Abnormal expression of ITGA9 was observed in various tumors including GBM and is closely related to tumor proliferation and angiogenesis (Wu et al., 2022). Furthermore, overexpression of ITGA3/ITGB1 plays a central role in promoting tube formation in tumor-associated EC in GBM. Blocking α3β1 function reduces sprout and tube formation of these EC, as well as vessel density in organotypic cultures of GBM. Furthermore, a mechanistic model suggests that integrin α3β1 promotes calcium influx and stimulates direct maturation of macropinosomes, promoting lysosomal exocytosis during vessel lumen formation (Bae et al., 2022). Consistent with our findings, the ITGA3 mRNA expressions in gliomas of WHO grading II, III and IV increased successively, with significant differences ($P<0.05$). Additionally, high expression of ITGA3 in GBM significantly and independently predicts poor survival in patients with astrocytoma (Xiang et al., 2022).

In addition, HA is known to strongly impact tumor development and progression by promoting cell proliferation, angiogenesis, lymphangiogenesis, chemotherapy resistance, and invasion of surrounding tissues (Jong et al., 2008; Ferrer, 2018). Tissue microarray data have shown high expression of HA, HAS1-3, hyaluronidases, and cluster of differentiation 44 (CD44) not only in malignant tissue but also in adjacent cerebral tissue of grades II - IV diffusely infiltrating astrocytomas (Valkonen et al., 2018). Highlighting the opposing effects of oligomeric HA and native HA, it has been proposed that the latter increases the levels of ceruloplasmin, a protein related to hypoxia, inflammation, and angiogenesis in gliomas, while oligomeric HA reduces its levels (Pibuel et al., 2021). In our study, we found that HAS1 expression is increased in EC under the influence of GBM. To date, there have been no studies directly relating HAS expression and EC in GBM.

Conversely, the role of MMP9 has long been studied in GBM angiogenesis (Thorns et al., 2003; Jiguet-Jiglaire et al., 2022). Increased expression of MMP9 has been correlated with increased angiogenesis (Annabi et al., 2009), and its expression is significantly induced by hypoxia in GBM (Emara and Allalunis-Turner, 2014). MMP9 and HAS1 have prognostic value in distinguishing between high and low expression cohorts of GBM patients. Although HA content has not shown prognostic value, an association between tumor grade and HAS1 and HAS2 has been observed. An increase in HAS2 expression has been correlated with poor prognosis in these patients (Pibuel et al., 2021; Bao et al., 2023). The expression of MMP9 has also been significantly associated with poor prognosis in GBM patients (Sun et al., 2019). Interestingly, the predictive value of MMP9 in a randomized phase III trial in patients with newly diagnosed GBM was correlated with the efficacy of bevacizumab, an antiangiogenic drug. Patients with low MMP9 levels had a significant 5.2-month OS benefit with

bevacizumab ($p = 0.0009$). In multivariate analysis, a significant interaction was observed between treatment and MMP9 ($p = 0.03$) for OS (Jiguet-Jiglaire et al., 2022).

Finally, elevated expression of lecticans, such as NCAN, has been reported in GBM (Wade et al., 2015). In this study, NCAN was the only ECM molecule for which low-expression patients had a worse prognosis. To date, there have been no studies directly linking NCAN expression to GBM survival. However, Sethi et al. (2022) observed differential regulation of O-glycopeptides for proteoglycans in GBM, with reduced O-glycopeptides for NCAN in GBM compared to controls (Sethi et al., 2022).

In summary, GBM ECM reduced the proliferation and branching properties of HBMEC over time. Increased expression of various ECM and ECM-related molecules was observed in EC from GBM, and these molecules were directly linked to the survival of GBM patients. This study identifies, for the first time, that the expressions of COL5A3, LAMA1, WNT9B, and HAS1 were increased in EC from GBM compared to normal brain EC, suggesting that these genes should be further studied in GBM angiogenesis. Additionally, except for NCAN, increased expression of ECM molecules was associated with shorter survival time in patients with GBM. This study also pioneers the demonstration that NCAN and COL27A1 are potential new ECM biomarkers to assist in GBM prognosis.

Figure Legends

Fig. 1. The GBM-derived ECM inhibited the proliferation of HBMEC at 24 h and 72 h. Following 72 h of GBM02 and HBMEC cell cultivation, a cell-free GBM and HBMEC ECM were obtained using a lysis buffer. Subsequently, HBMEC cells were cultured under both ECM conditions for (A) 24 h, (B) 48 h, and (C) 72 h. Immunofluorescence staining using phalloidin (actin, in red) and DAPI (nuclei, in blue) was performed. The nuclei were quantified using ImageJ and statistically analyzed (ANOVA). At 24 h, the GBM ECM exhibited reduced HBMEC proliferation compared to the gelatin coverslip control (** $p < 0.01$). Similarly, at 72 h, the GBM ECM showed a reduced capacity to stimulate HBMEC proliferation compared to the HBMEC ECM control (** $p < 0.01$).

Fig. 2. The *in silico* branching process of HBMEC cultivated under GBM ECM was simulated using Angiotool. (A) Previous immunofluorescence images were processed into a vascular network using the Angiotool software. The parameters of (B) vessel percentage area, (B) average vessel length, (C) number of junctions, and (D) total number of endpoints were analyzed. The GBM ECM decreased the average vessel length and the number of junctions at 48 h (***$p < 0.001$). Additionally, at 72 h, GBM ECM increased the number of junctions and inhibited the number of endpoints compared to controls.

Fig. 3. Under the influence of the GBM microenvironment, EC exhibited heightened expression of multiple ECM molecules. Using data obtained from the EndoDB database, we analyzed whether the GBM microenvironment would alter the EC ECM

transcriptome compared to normal brain EC. We observed increased expression of several ECM genes in ECs under GBM influence, including collagens (COL5A3, COL6A1, COL22A1, COL27A1), laminins (LAMA1 and LAMB1), and fibulins (FBLN1 and FBLN2). COL5A1 and NCAN showed no significant (ns) differences compared to the control. (** $p < 0.01$, *** $p < 0.001$).

Fig. 4. EC showed increased expression of ECM-related molecules, under the influence of GBM. We examined whether the GBM microenvironment alters the transcripts of ECM-degrading enzymes, ECM-stored factors, and integrin genes in EC. We utilized data from EndoDB to compare the EC transcriptomes of GBM specimens with those of normal brain EC. Our analysis revealed that EC from GBM exhibited heightened expression of the enzymes HAS1 and MMP9, as well as the growth factors TGFB1 and WNT9B. Additionally, ITGA3 expression was also increased in EC from GBM compared to controls (ns = non-significant, ** $p < 0.01$, *** $p < 0.001$).

Fig. 5. The increased expression of several ECM components was linked to a worse prognosis in GBM patients. We selected the same ECM molecules from the EC expression analysis to examine their direct influence on the OS of patients with GBM. OS curves were constructed using the Mantel-Cox test. Except for NCAN, high expression of ECM or ECM-related molecules was associated with poorer prognosis in GBM patients (*$p < 0.05$, ** $p < 0.01$, *** $p < 0.001$).

Acknowledgements

The authors express their gratitude to Prof. Vivaldo Moura Neto for providing the laboratory infrastructure and for being a personal source of inspiration.

Authors contributions

L.C.B. and M.H. performed the *in vitro* assays and analysis and the angiotool analysis. G.C.M. performed bioinformatic analysis. V.F. designed and supervised the work, wrote, and edited the manuscript.

References

Ahir BK, Engelhard HH, Lakka SS (2020) Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma. Mol Neurobiol 57.

Altieri F, Hansen T V., Vandin F (2019) NoMAS: A computational approach to find mutated subnetworks associated with survival in genome-wide cancer studies. Front Genet 10.

Alves TR, da Fonseca ACC, Nunes SS, da Silva AO, Dubois LGF, Faria J, Kahn SA, Viana NB, Marcondes J, Legrand C, Moura-Neto V, Morandi V (2011a) Tenascin-C in the extracellular matrix promotes the selection of highly proliferative and tubulogenesis-defective endothelial cells. Exp Cell Res.

Alves TR, Lima FRS, Kahn SA, Lobo D, Dubois LGF, Soletti R, Borges H, Neto VM (2011b) Glioblastoma cells: A heterogeneous and fatal tumor interacting with the parenchyma. In: Life Sciences, pp 532–539.

Annabi B, Lachambre MP, Plouffe K, Moumdjian R, Béliveau R (2009) Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res.

Bae E, Huang P, Müller-Greven G, Hambardzumyan D, Sloan AE, Nowacki AS, Marko N, Carlin CR, Gladson CL (2022) Integrin α3β1 promotes vessel formation of glioblastoma-associated endothelial cells through calcium-mediated macropinocytosis and lysosomal exocytosis. Nat Commun 13.

Baish JW, Stylianopoulos T, Lanning RM, Kamoun WS, Fukumura D, Munn LL, Jain RK (2011) Scaling rules for diffusive drug delivery in tumor and normal tissues. Proc Natl Acad Sci U S A 108.

Banerjee A, Kim BJ, Carmona EM, Cutting AS, Gurney MA, Carlos C, Feuer R, Prasadarao N V., Doran KS (2011) Bacterial Pili exploit integrin machinery to promote immune activation and efficient blood-brain barrier penetration. Nat Commun 2.

Bao X, Ran J, Kong C, Wan Z, Wang J, Yu T, Ruan S, Ding W, Xia L, Zhang D (2023) Pan-cancer analysis reveals the potential of hyaluronate synthase as therapeutic targets in human tumors. Heliyon 9.

Bassot A et al. (2023) Identification of a miRNA multi-targeting therapeutic strategy in glioblastoma. Cell Death Dis 14.

Behrem S, Žarković K, Eškinja N, Jonjić N (2005) Distribution pattern of tenascin-C in glioblastoma: Correlation with angiogenesis and tumor cell proliferation. Pathology and Oncology Research 11.

Bhattacharyya D, Hammond AT, Glick BS (2010) High-quality immunofluorescence of cultured cells. Methods Mol Biol 619.

Bougnaud S, Golebiewska A, Oudin A, Keunen O, Harter PN, Mäder L, Azuaje F, Fritah S, Stieber D, Kaoma T, Vallar L, Brons NHC, Daubon T, Miletic H, Sundstrøm T, Herold-Mende C, Mittelbronn M, Bjerkvig R, Niclou SP (2016) Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma. Oncotarget 7.

Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, Kleinschmidt-DeMasters BK, Perry A, Reifenberger G, Stupp R, von Deimling A, Weller M (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV." Acta Neuropathol 136.

Burghardt I, Schroeder JJ, Weiss T, Gramatzki D, Weller M (2021) A tumor-promoting role for soluble TβRIII in glioblastoma. Mol Cell Biochem 476.

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404 Available at: https://www.ncbi.nlm.nih.gov/pubmed/22588877.

Chen Q, Lu G, Cai Y, Li Y, Xu R, Ke Y, Zhang S (2014) MiR-124-5p inhibits the growth of high-grade gliomas through posttranscriptional regulation of LAMB1. Neuro Oncol 16.

De Bock K, Cauwenberghs S, Carmeliet P (2011) Vessel abnormalization: Another hallmark of cancer?. Molecular mechanisms and therapeutic implications. Curr Opin Genet Dev 21.

De Oliveira Rosario LV, Da Rosa BG, Goncalves TL, Matias DIL, Freitas C, Ferrer VP (2020) Glioblastoma factors increase the migration of human brain endothelial cells in vitro by increasing MMP-9/CXCR4 levels. Anticancer Res 40.

de Vega S, Kondo A, Suzuki M, Arai H, Jiapaer S, Sabit H, Nakada M, Ikeuchi T, Ishijima M, Arikawa-Hirasawa E, Yamada Y, Okada Y (2019) Fibulin-7 is overexpressed in glioblastomas and modulates glioblastoma neovascularization through interaction with angiopoietin-1. Int J Cancer 145.

Dinevska M, Widodo SS, Furst L, Cuzcano L, Fang Y, Mangiola S, Neeson PJ, Darcy PK, Ramsay RG, Hutchinson R, MacKay F, Christie M, Stylli SS, Mantamadiotis T (2023) Cell signaling activation and extracellular matrix remodeling underpin glioma tumor microenvironment heterogeneity and organization. Cellular Oncology 46.

Emara M, Allalunis-Turner J (2014) Effect of hypoxia on angiogenesis related factors in glioblastoma cells. Oncol Rep 31.

Faria J, Romão L, Martins S, Alves T, Mendes FA, De Faria GP, Hollanda R, Takiya C, Chimelli L, Morandi V, De Souza JM, Abreu JG, Neto VM (2006) Interactive properties of human glioblastoma cells with brain neurons in culture and neuronal modulation of glial laminin organization. Differentiation.

Ferrer P (2018) Glioma infiltration and extracellular matrix : key players and modulators. :1–24.

Fiscon G, Conte F, Licursi V, Nasi S, Paci P (2018) Computational identification of specific genes for glioblastoma stem-like cells identity. Sci Rep 8.

Folkins C, Shaked Y, Man S, Tang T, Lee CR, Zhu Z, Hoffman RM, Kerbel RS (2009) Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res 69.

Gamble JT, Reed-Harris Y, Barton CL, La Du J, Tanguay R, Greenwood JA (2018) Quantification of glioblastoma progression in zebrafish xenografts: Adhesion to

laminin alpha 5 promotes glioblastoma microtumor formation and inhibits cell invasion. Biochem Biophys Res Commun 506.

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:pl1 Available at: https://www.ncbi.nlm.nih.gov/pubmed/23550210.

Gonçalves TL, de Araújo LP, Pereira Ferrer V (2023) Tamoxifen as a modulator of CXCL12-CXCR4-CXCR7 chemokine axis: A breast cancer and glioblastoma view. Cytokine 170.

Han J, Alvarez-Breckenridge CA, Wang QE, Yu J (2015) TGF-β signaling and its targeting for glioma treatment. Am J Cancer Res 5.

Han X, Wang Q, Fang S, Wang J, Liu F, Zhang J, Jin G (2022) P4HA1 Regulates CD31 via COL6A1 in the Transition of Glioblastoma Stem-Like Cells to Tumor Endothelioid Cells. Front Oncol 12.

Harris GM, Raitman I, Schwarzbauer JE (2018) Cell-derived decellularized extracellular matrices. In: Methods in Cell Biology.

Ho KH, Chen PH, Shih CM, Lee YT, Cheng CH, Liu AJ, Lee CC, Chen KC (2022) miR-4286 is Involved in Connections Between IGF-1 and TGF-β Signaling for the Mesenchymal Transition and Invasion by Glioblastomas. Cell Mol Neurobiol 42.

Hu Y, Pioli PD, Siegel E, Zhang Q, Nelson J, Chaturbedi A, Mathews MS, Ro DI, Alkafeef S, Hsu N, Hamamura M, Yu L, Hess KR, Tromberg BJ, Linskey ME, Zhou YH (2011) EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment. Mol Cancer 10.

Huang M, Zhang D, Wu JY, Xing K, Yeo E, Li C, Zhang L, Holland E, Yao L, Qin L, Binder ZA, O'Rourke DM, Brem S, Koumenis C, Gong Y, Fan Y (2020) Wnt-mediated endothelial transformation into mesenchymal stem cell–like cells induces chemoresistance in glioblastoma. Sci Transl Med 12.

Hunt M, Wylęgała A, Wylęgała E, Teper S (2022) 1-Year Fixed-Regimen Bevacizumab Treatment in DME-Vascular Network Image Analysis in Optical Coherence Tomography Angiography Study. J Clin Med 11.

Jiguet-Jiglaire C et al. (2022) Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study. Acta Neuropathol Commun 10.

Jong A, Wu CH, Shackleford GM, Kwon-Chung KJ, Chang YC, Chen HM, Ouyang Y, Huang SH (2008) Involvement of human CD44 during Cryptococcus neoformans infection of brain microvascular endothelial cells. Cell Microbiol 10.

Karlsson M et al. (2021) A single–cell type transcriptomics map of human tissues. Sci Adv 7.

Kawataki T, Yamane T, Naganuma H, Rousselle P, Andurén I, Tryggvason K, Patarroyo M (2007) Laminin isoforms and their integrin receptors in glioma cell migration and

invasiveness: Evidence for a role of α5-laminin(s) and α3β1 integrin. Exp Cell Res 313.

Ke C, Luo J ran, Cen Z wen, Li Y, Cai H ping, Wang J, Chen F rong, Siegel ER, Le KN, Winokan JR, Gibson GJ, McSwain AE, Afrasiabi K, Linskey ME, Zhou YX, Chen Z ping, Zhou YH (2020) Dual antivascular function of human fibulin-3 variant, a potential new drug discovery strategy for glioblastoma. Cancer Sci 111.

Khan S, Taverna F, Rohlenova K, Treps L, Geldhof V, De Rooij L, Sokol L, Pircher A, Conradi LC, Kalucka J, Schoonjans L, Eelen G, Dewerchin M, Karakach T, Li X, Goveia J, Carmeliet P (2019) EndoDB: A database of endothelial cell transcriptomics data. Nucleic Acids Res 47.

Kretschmer M, Rüdiger D, Zahler S (2021) Mechanical aspects of angiogenesis. Cancers (Basel) 13.

Labussière M, Cheneau C, Prahst C, Gállego Pérez-Larraya J, Farina P, Lombardi G, Mokhtari K, Rahimian A, Delattre JY, Eichmann A, Sanson M (2016) Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma. Cancer Invest 34.

Lakka SS, Rao JS (2008) Antiangiogenic therapy in brain tumors. Expert Rev Neurother 8.

Lee SY, Park JH, Cho KH, Kim H, Shin HK (2022) Isolinderalactone inhibits glioblastoma cell supernatant-induced angiogenesis. Oncol Lett 24.

Liu D, Pearlman E, Diaconu E, Guo K, Mori H, Haqqi T, Markowitz S, Willson J, Sy MS (1996) Expression of hyaluronidase by tumor cells induces angiogenesis in vivo. Proc Natl Acad Sci U S A 93.

Liu H, Zeng Z, Sun P (2023) Prognosis and immunoinfiltration analysis of angiogene-related genes in grade 4 diffuse gliomas. Aging 15:9842–9857.

Ljubimova JY, Fujita M, Khazenzon NM, Ljubimov A V., Black KL (2006) Changes in laminin isoforms associated with brain tumor invasion and angiogenesis. Frontiers in Bioscience 11.

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, Von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol 23.

Mammoto T, Jiang A, Jiang E, Panigrahy D, Kieran MW, Mammoto A (2013) Role of collagen matrix in tumor angiogenesis and glioblastoma multiforme progression. American Journal of Pathology 183.

Manoranjan B, Provias JP (2022) β-Catenin marks proliferating endothelial cells in glioblastoma. Journal of Clinical Neuroscience 98.

Marino S, Menna G, Di Bonaventura R, Lisi L, Mattogno P, Figà F, Bilgin L, D'Alessandris QG, Olivi A, Della Pepa GM (2023) The Extracellular Matrix in

Glioblastomas: A Glance at Its Structural Modifications in Shaping the Tumoral Microenvironment—A Systematic Review. Cancers (Basel) 15.

Mazzone M et al. (2009) Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization. Cell 136.

McCord M, Mukouyama YS, Gilbert MR, Jackson S (2017) Targeting WNT signaling for multifaceted glioblastoma therapy. Front Cell Neurosci 11.

Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF (2010) Heterogeneity of the tumor vasculature. Semin Thromb Hemost 36.

Onishi M, Kurozumi K, Ichikawa T, Date I (2013) Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme. Neurol Med Chir (Tokyo) 53.

Pan YB, Zhang CH, Wang SQ, Ai PH, Chen K, Zhu L, Sun ZL, Feng DF (2018) Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma. J Neurooncol 137.

Paolillo M, Serra M, Schinelli S (2016) Integrins in glioblastoma: Still an attractive target? Pharmacol Res 113.

Papetti M, Herman IM (2002) Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 282.

Patarroyo M, Tryggvason K, Virtanen I (2002) Laminin isoforms in tumor invasion, angiogenesis and metastasis. Semin Cancer Biol 12.

Pedron S, Harley BAC (2013) Impact of the biophysical features of a 3D gelatin microenvironment on glioblastoma malignancy. J Biomed Mater Res A 101.

Pen A, Moreno MJ, Martin J, Stanimirovic DB (2007) Molecular markers of extracellular matrix remodeling in glioblastoma vessels: Microarray study of laser-captured glioblastoma vessels. Glia 55.

Pepper MS, Vassalli JD, Orci L, Montesano R (1993) Biphasic effect of transforming growth factor-β1 on in vitro angiogenesis. Exp Cell Res 204.

Petrik J, Campbell NE, Kellenberger L, Greenaway J, Moorehead RA, Linnerth-Petrik NM (2010) Extracellular matrix proteins and tumor angiogenesis. J Oncol.

Pibuel MA, Poodts D, Díaz M, Hajos SE, Lompardía SL (2021) The scrambled story between hyaluronan and glioblastoma. Journal of Biological Chemistry 296.

Rempel SA, Dudas S, Ge S, Gutiérrez JA (2000) Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clinical Cancer Research 6.

Ren T, Lin S, Wang Z, Shang A (2016) Differential proteomics analysis of low- and high-grade of astrocytoma using iTRAQ quantification. Onco Targets Ther 9.

Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, De Maria R (2010) Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468.

Riganti C, Salaroglio IC, Pinzòn-Daza ML, Caldera V, Campia I, Kopecka J, Mellai M, Annovazzi L, Couraud PO, Bosia A, Ghigo D, Schiffer D (2014) Temozolomide down-regulates P-glycoprotein in human blood-brain barrier cells by disrupting Wnt3 signaling. Cellular and Molecular Life Sciences 71.

Rupp T, Langlois B, Koczorowska MM, Radwanska A, Sun Z, Hussenet T, Lefebvre O, Murdamoothoo D, Arnold C, Klein A, Biniossek ML, Hyenne V, Naudin E, Velazquez-Quesada I, Schilling O, Van Obberghen-Schilling E, Orend G (2016) Tenascin-C Orchestrates Glioblastoma Angiogenesis by Modulation of Pro- and Anti-angiogenic Signaling. Cell Rep.

Schaffenrath J, Wyss T, He L, Rushing EJ, Delorenzi M, Vasella F, Regli L, Neidert MC, Keller A (2021) Blood-brain barrier alterations in human brain tumors revealed by genome-wide transcriptomic profiling. Neuro Oncol 23.

Scrideli CA, Carlotti CG, Okamoto OK, Andrade VS, Cortez MAA, Motta FJN, Lucio-Eterovic AK, Neder L, Rosemberg S, Oba-Shinjo SM, Marie SKN, Tone LG (2008) Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: Identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR. J Neurooncol 88.

Senger DR, Davis GE (2011) Angiogenesis. Cold Spring Harb Perspect Biol 3.

Sethi MK, Downs M, Shao C, Hackett WE, Phillips JJ, Zaia J (2022) In-Depth Matrisome and Glycoproteomic Analysis of Human Brain Glioblastoma Versus Control Tissue. Molecular and Cellular Proteomics 21.

Seystahl K, Weller M (2012) Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma? Expert Opin Investig Drugs 21.

Spainhour JCG, Qiu P (2016) Identification of gene-drug interactions that impact patient survival in TCGA. BMC Bioinformatics 17.

Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa SI, Kubo H, Achen MG (2001) VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7.

Stins MF, Badger J, Sik Kim K (2001) Bacterial invasion and transcytosis in transfected human brain microvascular endothelial cells. Microb Pathog 30.

Stratmann A, Risau W, Plate KH (1998) Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. American Journal of Pathology 153.

Stylianopoulos T, Jain RK (2013) Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci U S A 110.

Sun J, Zhao B, Du K, Liu P (2019) TRAF6 correlated to invasion and poor prognosis of glioblastoma via elevating MMP9 expression. Neuroreport 30.

Takano S, Yamashita T, Ohneda O (2010) Molecular therapeutic targets for glioma angiogenesis. J Oncol.

Tchaicha JH, Reyes SB, Shin J, Hossain MG, Lang FF, McCarty JH (2011) Glioblastoma angiogenesis and tumor cell invasiveness are differentially regulated by β8 integrin. Cancer Res 71.

Testa E, Palazzo C, Mastrantonio R, Viscomi MT (2022) Dynamic Interactions between Tumor Cells and Brain Microvascular Endothelial Cells in Glioblastoma. Cancers (Basel) 14.

Thorns V, Walter GF, Thorns C (2003) Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in Human Astrocytic and Oligodendroglial Gliomas. Anticancer Res 23.

Towner RA, Jensen RL, Vaillant B, Colman H, Saunders D, Giles CB, Wren JD (2013) Experimental validation of 5 in-silico predicted glioma biomarkers. Neuro Oncol 15.

Tsai HF, Chang YC, Li CH, Chan MH, Chen CL, Tsai WC, Hsiao M (2021) Type V collagen alpha 1 chain promotes the malignancy of glioblastoma through PPRC1-ESM1 axis activation and extracellular matrix remodeling. Cell Death Discov 7.

Valkonen M, Haapasalo H, Rilla K, Tyynelä-Korhonen K, Soini Y, Pasonen-Seppänen S (2018) Elevated expression of hyaluronan synthase 2 associates with decreased survival in diffusely infiltrating astrocytomas. BMC Cancer 18.

Virga J, Bognár L, Hortobágyi T, Zahuczky G, Csősz É, Kalló G, Tóth J, Hutóczki G, Reményi-Puskár J, Steiner L, Klekner A (2017) Prognostic Role of the Expression of Invasion-Related Molecules in Glioblastoma. J Neurol Surg A Cent Eur Neurosurg 78.

Wade A, Engler JR, Tran VM, Phillips JJ (2015) Measuring sulfatase expression and invasion in glioblastoma. Methods in Molecular Biology 1229.

Wan Z, Zuo X, Wang S, Zhou L, Wen X, Yao Y, Song J, Gu J, Wang Z, Liu R, Luo C (2023) Identification of angiogenesis-related genes signature for predicting survival and its regulatory network in glioblastoma. Cancer Med 12.

Weathers SP, de Groot J (2015) VEGF manipulation in glioblastoma. ONCOLOGY (United States) 29.

Wen PY et al. (2020) Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol 22.

Wu Y, Chen J, Tan F, Wang B, Xu W, Yuan C (2022) ITGA9: Potential Biomarkers and Therapeutic Targets in Different Tumors. Curr Pharm Des 28.

Xiang Z, Zhongwei W, Haigang C, Shupeng Z, Baozhe J (2022) Integrin alpha 3 expression in glioma and its prognostic value in glioma patients. Chinese Journal of Neuromedicine 21.

Yang W, Yee AJ (2013) Versican V2 isoform enhances angiogenesis by regulating endothelial cell activities and fibronectin expression. FEBS Lett 587.

Yang XJ, Chen GL, Yu SC, Xu C, Xin YH, Li TT, Shi Y, Gu A, Duan JJ, Qian C, Cui YH, Zhang X, Bian XW (2013) TGF-β1 enhances tumor-induced angiogenesis via JNK pathway and macrophage infiltration in an improved zebrafish embryo/xenograft glioma model. Int Immunopharmacol 15.

Yousif LF, Di Russo J, Sorokin L (2013) Laminin isoforms in endothelial and perivascular basement membranes. Cell Adh Migr 7.

Yunker CK, Golembieski W, Lemke N, Schultz CR, Cazacu S, Brodie C, Rempel SA (2008) SPARC-induced increase in glioma matrix and decrease in vascularity are associated with reduced VEGF expression and secretion. Int J Cancer 122.

Zagzag D, Friedlander DR, Miller DC, Dosik J, Cangiarella J, Kostianovsky M, Cohen H, Grumet M, Greco MA (1995) Tenascin Expression in Astrocytomas Correlates with Angiogenesis. Cancer Res 55.

Zhang Y, Zhang N, Dai B, Liu M, Sawaya R, Xie K, Huang S (2008) FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. Cancer Res 68.

Zolotovskaia MA, Kovalenko MA, Tkachev VS, Simonov AM, Sorokin MI, Kim E, Kuzmin D V., Karademir-Yilmaz B, Buzdin AA (2022) Next-Generation Grade and Survival Expression Biomarkers of Human Gliomas Based on Algorithmically Reconstructed Molecular Pathways. Int J Mol Sci 23.

Zudaire E, Gambardella L, Kurcz C, Vermeren S (2011) A computational tool for quantitative analysis of vascular networks. PLoS One 6.


Gelatin
GBM
HBMEC
A
24 h
10 µm
B
48 h
10 µm
C
72 h
10 µm
Number of cells
Gelatin
Gelatin + GBM
Gelatin + HBMEC
**


A
Outline
Skeleton
Branching points
Boundary
B
24h
48h
72h
Percentage area
C
Average Vessels Length
D
Number of junctions
E
Number of endpoints
Gelatin
Gelatin + GBM
Gelatin + HBMEC


COL5A1
ns
COL5A3
* * *
COL6A1
* *
COL22A1
* * *
COL27A1
* * *
LAMB1
* * *
LAMA1
* * *
NCAN
ns
FBLN1
* * *
FBLN2
* *
HAS1
* *
MMP9
* * *
TIMP4
ns
TGFB1
* *
WNT9B
* *
ITGA3
* *
Expression
Control
GBM


COL5A1/A3,COL6A1
COL5A1 high
COL5A1 low
COL5A3 high
COL5A3 low
COL6A1 high
COL6A1 low
p = 0.0004 ***
COL22/27A1
COL22A1 high
COL22A1 low
COL27A1 high
COL27A1 low
p <0.0001 ****
FBLN
FBLN1 high
FBLN1 low
FBLN2 high
FBLN2 low
p = 0.0055 **
ITGA3
ITGA3 high
ITGA3 low
p = 0.0038 **
LAMA1/LAMB1
LAMA1 high
LAMA1 low
LAMB1 high
LAMB1 low
p = 0.0039 **
NCAN
NCAN high
NCAN low
p = 0.0124 *
TGFB1
TGFB1 high
TGFB1 low
p = 0.0047 **
MMP9
MMP9 high
MMP9 low
p = 0.0149 *
HAS1
HAS1 high
HAS1 low
p = 0.0313 *
Percent survival
Months
0
50
100
0
20
40
60
80
100